A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma
FRACTION: Study of Drug Combinations in Patients with Advanced Renal Cell Carcinoma
Sponsor: BMS
Enrolling: Male and Female Patients
IRB Number: AAAR5002
U.S. Govt. ID: NCT02996110
Contact: Emerson Lim MD: 212-305-5098 / el2342@cumc.columbia.edu
Additional Study Information: We are doing this study to test a drug called MGD009. MGD009 is like an antibody, which is a protein in your blood that helps get rid of germs in your body. MGD009 is made to attach to cancer cells and to T-cells, which are a part of your immune system. Certain T cells have the ability to kill other cells, including cancer cells. By attaching to cancer cells and T cells, MGD009 may help your immune system kill the cancer cells. Though MGD009 has been studied in animals, this study will be the first time MGD009 will be given to humans to be tested as a possible treatment for cancer. The purpose of the study is to find the answers to these research questions: What are the side effects of MGD009? At what dose levels are side effects of MGD009 observed? What is the maximum dose of MGD009 that can be given to patients without serious side effects? How long does MGD009 stay in your blood?
This study is closed
Emerson Lim, MD
Do You Qualify?
Do you have advanced or metastatic renal cell carcinoma (RCC)? Yes No
Have you received prior treatment with IL-2, INF, or radiotherapy that ended 4 weeks prior to randomization? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Emerson Lim MD